# The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

> **NCT04830267** · PHASE2 · RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT04830267
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830267, "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04830267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*